(Total Views: 504)
Posted On: 04/09/2018 1:13:00 PM
Post# of 30066
Webcast!
Amarantus to Present at The Microcap Conference in NYC
APRIL 09, 2018
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries, today announced that its President & CEO Gerald E. Commissiong will present a corporate overview at The Microcap Conference on April 10, 2018 at 9:30am in Track 1 at the JW Marriott Essex House in New York, NY.
The presentation will be webcast live at http://www.investorcalendar.com/event/27690 and will be archived for 90 days following the presentation. Interested investors may contact the Company by email at info@amarantus.com or by calling and leaving a message at 917-686-5317.
The Company's CEO Gerald Commissiong, and interim-COO/CFO Barney Monte have remaining availability for one-on-one meetings with investors on Tuesday April 10, 2018.
Amarantus to Present at The Microcap Conference in NYC
APRIL 09, 2018
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries, today announced that its President & CEO Gerald E. Commissiong will present a corporate overview at The Microcap Conference on April 10, 2018 at 9:30am in Track 1 at the JW Marriott Essex House in New York, NY.
The presentation will be webcast live at http://www.investorcalendar.com/event/27690 and will be archived for 90 days following the presentation. Interested investors may contact the Company by email at info@amarantus.com or by calling and leaving a message at 917-686-5317.
The Company's CEO Gerald Commissiong, and interim-COO/CFO Barney Monte have remaining availability for one-on-one meetings with investors on Tuesday April 10, 2018.
(4)
(0)
